A single-arm phase II trial of Atezolizumab and Bevacizumab with combined radiotherapy in advanced hepatocellular carcinoma with portal vein invasio
Not Applicable
- Conditions
- Neoplasms
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 51
Inclusion Criteria
(1) age =19
(2) clinically or histologically diagnosed HCC
(3) HCC with Vp2-Vp4 portal vein invasion
(4) intact liver function with Child-Pugh class A
(5) adequate size of RT field
(6) adequate liver function
; AST/ALT =5 times the upper limits of normal)
; no coagulopathy
(7) intact performance with ECOG below 2
(8) non-pregnant with acceptable contraception in premenopausal women)
(9) without other life-threatening diseases
(10) ability to provide written informed consent and to comply with all study conditions.
Exclusion Criteria
(1) Active uncontrolled infection; (2) Current or history (< or = 5 years) of advanced malignancies in the other organs; (3) History of liver transplantation; (4) miliary HCC which incompatible external beam RT
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival
- Secondary Outcome Measures
Name Time Method Overall survival;Objective response rate;Safety and adverse event